May 13, 2024
|
MacroGenics to Participate in Upcoming Investor Conferences
|
|
May 09, 2024
|
MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study Data
|
|
May 03, 2024
|
MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call
|
|
Apr 03, 2024
|
MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
|
|
Mar 07, 2024
|
MacroGenics Provides Update on Corporate Progress and 2023 Financial Results
|
|
Mar 01, 2024
|
MacroGenics to Participate in Upcoming Investor Conferences
|
|
Feb 27, 2024
|
MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call
|
|
Feb 02, 2024
|
MacroGenics to Participate in Upcoming Investor Conference
|
|
Jan 08, 2024
|
MacroGenics to Participate in Upcoming Investor Conference
|
|
Nov 06, 2023
|
MacroGenics Provides Update on Corporate Progress and Third Quarter 2023 Financial Results
|
|
Nov 02, 2023
|
MacroGenics to Participate in Upcoming Investor Conferences
|
|
Oct 31, 2023
|
MacroGenics Announces Date of Third Quarter 2023 Financial Results Conference Call
|
|
Sep 05, 2023
|
MacroGenics Announces Achievement of $15 Million Milestone Related to Gilead’s Nomination of a Bispecific Research Program
|
|
Aug 31, 2023
|
MacroGenics to Participate in Upcoming Investor Conferences
|
|
Aug 09, 2023
|
MacroGenics Provides Update on Corporate Progress and Second Quarter 2023 Financial Results
|
|
Jul 31, 2023
|
MacroGenics Announces Date of Second Quarter 2023 Financial Results Conference Call
|
|
May 09, 2023
|
MacroGenics Provides Update on Corporate Progress and First Quarter 2023 Financial Results
|
|
May 04, 2023
|
MacroGenics Announces Date of First Quarter 2023 Financial Results Conference Call
|
|
Apr 24, 2023
|
MacroGenics to Participate in Upcoming Investor Conferences
|
|
Mar 22, 2023
|
MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ™ (retifanlimab-dlwr)
|
|
Mar 15, 2023
|
MacroGenics Provides Corporate Update and 2022 Financial Results
|
|
Mar 08, 2023
|
MacroGenics Announces Sale of TZIELD™ Royalty Interest for up to $200 Million
|
|
Mar 07, 2023
|
MacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference Call
|
|
Mar 02, 2023
|
MacroGenics to Participate in Upcoming Investor Conferences
|
|
Feb 13, 2023
|
MacroGenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients with Metastatic Castration-Resistant Prostate Cancer to be Presented at ASCO Genitourinary Cancers Symposium
|
|